Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant

por Riddell, Peter, Vasudevan-Nampoothiri, Ram, Ma, Jin, Singer, Lianne G., Lipton, Jeff H., Juvet, Stephen C.
Publicado 2021

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

por Cortes, Jorge E., Lipton, Jeff H., Kota, Vamsi, Castagnetti, Fausto, Assouline, Sarit, Brümmendorf, Tim H., Leip, Eric, Viqueira, Andrea, Gambacorti-Passerini, Carlo
Publicado 2023

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or int...

por Kantarjian, Hagop M., Mamolo, Carla M., Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Brümmendorf, Tim H., Su, Yun, Reisman, Arlene L., Shapiro, Mark, Lipton, Jeff H.
Publicado 2017

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

por Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo
Publicado 2016

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

por Gambacorti-Passerini, Carlo, Cortes, Jorge E, Lipton, Jeff H, Dmoszynska, Anna, Wong, Raymond S, Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M, Brümmendorf, Tim H
Publicado 2014

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

por Brümmendorf, Tim H., Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Kim, Dong‐Wook, Schafhausen, Philippe, Conlan, Maureen G., Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Gambacorti‐Passerini, Carlo, Lipton, Jeff H.
Publicado 2015

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

por Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean
Publicado 2018